All Pharma News
Ribon rids preclinical work, trims staff to focus on two PARP inhibitors

Ribon rids preclinical work, trims staff to focus on two PARP inhibitors
Kyle LaHucik ENDPTS
28 Jul 2023
Share Share
Ribon Doses First Patient in Phase 1 Clinical Study with RBN-3143

Ribon Doses First Patient in Phase 1 Clinical Study with RBN-3143
BUSINESSWIRE
09 Mar 2023
Share Share
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer
BUSINESSWIRE
30 Jan 2023
Share Share
Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension

Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension
Tyler Patchen ENDPTS
30 Jan 2023
Share Share
Ribon Announces Acquisition of Pre-Clinical CD38 Program by Boehringer

Ribon Announces Acquisition of Pre-Clinical CD38 Program by Boehringer
BUSINESSWIRE
29 Nov 2022
Share Share
Ribon Therapeutics Announces Presentation of Preclinical Data on RBN-3143

Ribon Therapeutics Announces Presentation of Preclinical Data on RBN-3143
BUSINESSWIRE
06 Sep 2022
Share Share
Ribon Tx Announces Presentations at the AACR

Ribon Tx Announces Presentations at the AACR
BUSINESSWIRE
11 Apr 2022
Share Share
Ribon Tx Initiates Phase 1b/2 Study of RBN-2397+Pembrolizumab in SCC

Ribon Tx Initiates Phase 1b/2 Study of RBN-2397+Pembrolizumab in SCC
BUSINESSWIRE
29 Mar 2022
Share Share
Ribon taps former Novartis VP Raman as CEO

Ribon taps former Novartis VP Raman as CEO
Max Bayer FIERCEBIOTECH
18 Feb 2022
Share Share
Ribon Therapeutics Announces CEO Transition for Its Next Phase of Growth

Ribon Therapeutics Announces CEO Transition for Its Next Phase of Growth
BUSINESSWIRE
17 Feb 2022
Share Share